Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL

NCT04930653 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT04930653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04930653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
October 19, 2022
Completion date
June 15, 2028
Enrollment
34 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

folliculotropic mycosis fungoides, primary cutaneous t-cell non-hodgkin lymphoma, sezary syndrome, stage ib mycosis fungoides and sezary syndrome ajcc v8, stage ii mycosis fungoides and sezary syndrome ajcc v8, stage iia mycosis fungoides and sezary syndrome ajcc v8, stage iib mycosis fungoides and sezary syndrome ajcc v8, transformed mycosis fungoides